Cargando…

Establishment of SLC15A1/PEPT1-Knockout Human-Induced Pluripotent Stem Cell Line for Intestinal Drug Absorption Studies

Because many peptide and peptide-mimetic drugs are substrates of peptide transporter 1, it is important to evaluate the peptide transporter 1-mediated intestinal absorption of drug candidates in the early phase of drug development. Although intestinal cell lines treated with inhibitors of peptide tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawai, Kanae, Negoro, Ryosuke, Ichikawa, Moe, Yamashita, Tomoki, Deguchi, Sayaka, Harada, Kazuo, Hirata, Kazumasa, Takayama, Kazuo, Mizuguchi, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6926248/
https://www.ncbi.nlm.nih.gov/pubmed/31890740
http://dx.doi.org/10.1016/j.omtm.2019.11.008
_version_ 1783482055561052160
author Kawai, Kanae
Negoro, Ryosuke
Ichikawa, Moe
Yamashita, Tomoki
Deguchi, Sayaka
Harada, Kazuo
Hirata, Kazumasa
Takayama, Kazuo
Mizuguchi, Hiroyuki
author_facet Kawai, Kanae
Negoro, Ryosuke
Ichikawa, Moe
Yamashita, Tomoki
Deguchi, Sayaka
Harada, Kazuo
Hirata, Kazumasa
Takayama, Kazuo
Mizuguchi, Hiroyuki
author_sort Kawai, Kanae
collection PubMed
description Because many peptide and peptide-mimetic drugs are substrates of peptide transporter 1, it is important to evaluate the peptide transporter 1-mediated intestinal absorption of drug candidates in the early phase of drug development. Although intestinal cell lines treated with inhibitors of peptide transporter 1 are widely used to examine whether drug candidates are substrates for peptide transporter 1, these inhibitors are not sufficiently specific for peptide transporter 1. In this study, to generate a more precise evaluation model, we established peptide transporter 1-knockout induced pluripotent stem cells (iPSCs) by using a CRISPR-Cas9 system and differentiated the cells into intestinal epithelial-like cells. The permeability value and uptake capacity of glycylsarcosine (substrate of peptide transporter 1) in peptide transporter 1-knockout intestinal epithelial-like cells were significantly lower than those in wild-type intestinal epithelial-like cells, suggesting that peptide transporter 1 was successfully depleted in the epithelial cells. Taken together, our model can be useful in the development of peptide and peptide-mimetic drugs.
format Online
Article
Text
id pubmed-6926248
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-69262482019-12-30 Establishment of SLC15A1/PEPT1-Knockout Human-Induced Pluripotent Stem Cell Line for Intestinal Drug Absorption Studies Kawai, Kanae Negoro, Ryosuke Ichikawa, Moe Yamashita, Tomoki Deguchi, Sayaka Harada, Kazuo Hirata, Kazumasa Takayama, Kazuo Mizuguchi, Hiroyuki Mol Ther Methods Clin Dev Article Because many peptide and peptide-mimetic drugs are substrates of peptide transporter 1, it is important to evaluate the peptide transporter 1-mediated intestinal absorption of drug candidates in the early phase of drug development. Although intestinal cell lines treated with inhibitors of peptide transporter 1 are widely used to examine whether drug candidates are substrates for peptide transporter 1, these inhibitors are not sufficiently specific for peptide transporter 1. In this study, to generate a more precise evaluation model, we established peptide transporter 1-knockout induced pluripotent stem cells (iPSCs) by using a CRISPR-Cas9 system and differentiated the cells into intestinal epithelial-like cells. The permeability value and uptake capacity of glycylsarcosine (substrate of peptide transporter 1) in peptide transporter 1-knockout intestinal epithelial-like cells were significantly lower than those in wild-type intestinal epithelial-like cells, suggesting that peptide transporter 1 was successfully depleted in the epithelial cells. Taken together, our model can be useful in the development of peptide and peptide-mimetic drugs. American Society of Gene & Cell Therapy 2019-11-21 /pmc/articles/PMC6926248/ /pubmed/31890740 http://dx.doi.org/10.1016/j.omtm.2019.11.008 Text en © 2019 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Kawai, Kanae
Negoro, Ryosuke
Ichikawa, Moe
Yamashita, Tomoki
Deguchi, Sayaka
Harada, Kazuo
Hirata, Kazumasa
Takayama, Kazuo
Mizuguchi, Hiroyuki
Establishment of SLC15A1/PEPT1-Knockout Human-Induced Pluripotent Stem Cell Line for Intestinal Drug Absorption Studies
title Establishment of SLC15A1/PEPT1-Knockout Human-Induced Pluripotent Stem Cell Line for Intestinal Drug Absorption Studies
title_full Establishment of SLC15A1/PEPT1-Knockout Human-Induced Pluripotent Stem Cell Line for Intestinal Drug Absorption Studies
title_fullStr Establishment of SLC15A1/PEPT1-Knockout Human-Induced Pluripotent Stem Cell Line for Intestinal Drug Absorption Studies
title_full_unstemmed Establishment of SLC15A1/PEPT1-Knockout Human-Induced Pluripotent Stem Cell Line for Intestinal Drug Absorption Studies
title_short Establishment of SLC15A1/PEPT1-Knockout Human-Induced Pluripotent Stem Cell Line for Intestinal Drug Absorption Studies
title_sort establishment of slc15a1/pept1-knockout human-induced pluripotent stem cell line for intestinal drug absorption studies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6926248/
https://www.ncbi.nlm.nih.gov/pubmed/31890740
http://dx.doi.org/10.1016/j.omtm.2019.11.008
work_keys_str_mv AT kawaikanae establishmentofslc15a1pept1knockouthumaninducedpluripotentstemcelllineforintestinaldrugabsorptionstudies
AT negororyosuke establishmentofslc15a1pept1knockouthumaninducedpluripotentstemcelllineforintestinaldrugabsorptionstudies
AT ichikawamoe establishmentofslc15a1pept1knockouthumaninducedpluripotentstemcelllineforintestinaldrugabsorptionstudies
AT yamashitatomoki establishmentofslc15a1pept1knockouthumaninducedpluripotentstemcelllineforintestinaldrugabsorptionstudies
AT deguchisayaka establishmentofslc15a1pept1knockouthumaninducedpluripotentstemcelllineforintestinaldrugabsorptionstudies
AT haradakazuo establishmentofslc15a1pept1knockouthumaninducedpluripotentstemcelllineforintestinaldrugabsorptionstudies
AT hiratakazumasa establishmentofslc15a1pept1knockouthumaninducedpluripotentstemcelllineforintestinaldrugabsorptionstudies
AT takayamakazuo establishmentofslc15a1pept1knockouthumaninducedpluripotentstemcelllineforintestinaldrugabsorptionstudies
AT mizuguchihiroyuki establishmentofslc15a1pept1knockouthumaninducedpluripotentstemcelllineforintestinaldrugabsorptionstudies